Efficacy and Safety of Tacrolimus as Secondline Therapy for Patients With Autoimmune Hepatitis Pilot Study
Not Applicable
- Conditions
- Autoimmune Hepatitis
- Registration Number
- JPRN-UMIN000030743
- Lead Sponsor
- Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1.Liver cirrhosis 2.HBV , HCV, PBC, NASH 3.Arrergy of Tacrolimus 4.Arrergy of ciclosporin 5.Patents who treated with potassium-conserving diuretic 6.Pregnancy 7.Patients who hope of pregnancy 8.Severe infection 9.Patients who judge exclusion criteria by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of patients who had normal ALT at 2 weeks from initial tacrolimus treatment The duration which had normal ALT at 2 weeks from initial tacrolimus treatment The rate of patients who had normal IgG at 2 weeks from initial tacrolimus treatment The duration which had normal IgG at 2 weeks from initial tacrolimus treatment The rate of patients who had normal ALT at 2 years from initial tacrolimus treatment The rate of patients who had normal IgG at 2 years from initial tacrolimus treatment Safety
- Secondary Outcome Measures
Name Time Method